Stocks To Buy Now

Blog


Day 1 of LD Micro Main Event Full of Keynote Speakers, Hot Topic Panels, Small-Cap Presentations

LD Micro yesterday kicked-off its Main Event Small-Cap conference in Los Angeles, where several speakers addressed an audience of eager attendees, who were also given the opportunity to attend informative panels and presentations from about 20 small-cap companies.

The event opened up with financial analyst Andrew Wheeler discussing QE4 (the Fed’s bond-buying program), quantitative easing and how interest rates are impacting the economy. Up next was Tobias Carlisle, author of the website Greenbackd and the books Deep Value: Why Activists Investors and Other Contrarians Battle for Control of Losing Corporations and Quantitative Value: A Practitioner’s Guide to Automating Intelligent Investment and Eliminating Behavioral Errors.

Of course, it’s no investor conference without an array of investment options and enthusiastic executives. After the afternoon events, about 20 small-cap companies initiated three-days of company presentations from businesses covering a wide range of industries, including beverages, healthcare, technology, biotech, fitness and more.

Attendees were then privy to panels covering cannabis and uplisting, followed by evening speaking presentations by Adam Epstein, author and advisor to the boards of pre-IPO and small-cap companies, and David Weild, the man Forbes calls the “Father of the JOBS Act.”

Today’s schedule is chock-full of presentations from innovative, high potential companies from all over the United States and abroad. If you’re missing out on the event, head over to www.ldmicro.missionir.com and take a look at the presentation schedule and find out a bit about each company.

*Schedule is subject to change throughout the course of the event

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer

May 1, 2025

The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The market for treatments in this space is substantial, as rare diseases collectively affect millions of people worldwide. Among […]

Rotate your device 90° to view site.